PLAUR and prostate carcinoma: Further evidence from multiple tumor models of prostate cancer confirms that antibody-mediated disruption of uPAR (e.g., huATN-658) attenuates metastatic growth, particularly skeletal metastasis, by interfering with uPAR–integrin interactions and downstream effectors such as FAK, AKT, and MAPK [120].